Johnson & Johnson
JNJ159.340USD
+3.979+2.56%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
383.52BMarktkapitalisierung
27.27KGV TTM
mehr Informationen über Johnson & Johnson Unternehmen
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
Unternehmensinformationen
Unternehmens-codeJNJ
Name des UnternehmensJohnson & Johnson
IPO-datumSep 25, 1944
Gegründet am1887
CEOMr. Joaquin Boix Duato
Anzahl der mitarbeiter138100
WertpapierartOrdinary Share
GeschäftsjahresendeSep 25
AddresseOne Johnson & Johnson Plaza
StadtNEW BRUNSWICK
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl08933
Telefon17325242455
Websitehttps://www.jnj.com/
Unternehmens-codeJNJ
IPO-datumSep 25, 1944
Gegründet am1887
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
15.54K
+6.62%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
10.90K
+30.72%
Ms. Anne M. Mulcahy
Ms. Anne M. Mulcahy
Independent Director
Independent Director
8.41K
+3.87%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
15.54K
+6.62%
Umsatzaufteilung
Währung: USDUpdate-Zeit: 22 hours ago
Währung: USDUpdate-Zeit: 22 hours ago
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
Nach RegionUSD
Name
Umsatz
Anteil
United States
50.30B
56.63%
International
38.52B
43.37%
Europe
20.21B
22.76%
Asia-Pacific, Africa
13.59B
15.30%
Western Hemisphere, excluding U.S.
4.71B
5.31%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.62%
State Street Global Advisors (US)
5.58%
BlackRock Institutional Trust Company, N.A.
5.39%
Geode Capital Management, L.L.C.
2.39%
State Farm Insurance Companies
1.31%
Other
75.70%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.62%
State Street Global Advisors (US)
5.58%
BlackRock Institutional Trust Company, N.A.
5.39%
Geode Capital Management, L.L.C.
2.39%
State Farm Insurance Companies
1.31%
Other
75.70%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
33.37%
Investment Advisor
28.76%
Research Firm
3.01%
Pension Fund
2.28%
Bank and Trust
2.12%
Insurance Company
1.50%
Sovereign Wealth Fund
1.36%
Hedge Fund
0.75%
Foundation
0.43%
Other
26.41%
Institutionelle Beteiligung
Update-Zeit: Thu, Feb 20
Update-Zeit: Thu, Feb 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
5844
1.79B
74.15%
+9.45M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
2022Q4
5447
1.87B
71.55%
+6.54M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
231.82M
9.62%
+1.80M
+0.78%
Dec 31, 2024
State Street Global Advisors (US)
134.46M
5.58%
+210.35K
+0.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
130.00M
5.39%
+2.12M
+1.65%
Dec 31, 2024
Geode Capital Management, L.L.C.
57.67M
2.39%
+1.56M
+2.78%
Dec 31, 2024
State Farm Insurance Companies
31.68M
1.31%
--
--
Dec 31, 2024
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Wellington Management Company, LLP
24.36M
1.01%
+431.20K
+1.80%
Dec 31, 2024
JP Morgan Asset Management
24.04M
1%
+5.40M
+29.00%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.91M
0.95%
-654.88K
-2.78%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
19.88M
0.82%
+587.38K
+3.05%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Wed, Apr 2
Update-Zeit: Wed, Apr 2
Name
Anteil
iShares U.S. Pharmaceuticals ETF
24.61%
FT Vest DJIA Dogs 10 Target Income ETF
13.93%
First Trust NASDAQ Pharmaceuticals ETF
8.4%
American Century Focused Large Cap Value ETF
7.72%
VanEck Pharmaceutical ETF
7.37%
Proshares Ultra Health Care
7.32%
Health Care Select Sector SPDR Fund
7.31%
iShares Core High Dividend ETF
7.19%
iShares U.S. Healthcare ETF
7.11%
JPMorgan Healthcare Leaders ETF
6.46%
Mehr Anzeigen
iShares U.S. Pharmaceuticals ETF
Anteil24.61%
FT Vest DJIA Dogs 10 Target Income ETF
Anteil13.93%
First Trust NASDAQ Pharmaceuticals ETF
Anteil8.4%
American Century Focused Large Cap Value ETF
Anteil7.72%
VanEck Pharmaceutical ETF
Anteil7.37%
Proshares Ultra Health Care
Anteil7.32%
Health Care Select Sector SPDR Fund
Anteil7.31%
iShares Core High Dividend ETF
Anteil7.19%
iShares U.S. Healthcare ETF
Anteil7.11%
JPMorgan Healthcare Leaders ETF
Anteil6.46%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
56.79B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten